Personalized medicine: potential, barriers and contemporary issues

Area of Science:

• Pharmacogenomics and Personalized Medicine

Background:

• Personalized medicine leverages advances in understanding individual biological differences.
• Potential benefits include reduced drug toxicity, enhanced efficacy, healthcare sustainability, and improved drug development.
• Significant barriers like cost, complexity, evidence requirements, and education hinder clinical translation of pharmacogenomic tests.

Purpose of the Study:

• To explore the benefits and barriers of personalized medicine.
• To contextualize these issues using contemporary pharmacogenetic test examples.
• To highlight areas needing clarification, including regulatory requirements and marker development.

Main Methods:

• Review of personalized medicine advancements and challenges.
• Analysis of three pharmacogenetic test cases: UGT1A1/irinotecan, CYP2C19/clopidogrel, and CYP2C9/warfarin.
• Discussion of regulatory and educational needs for clinical implementation.

Main Results:

• Pharmacogenomic tests show promise but face hurdles in clinical adoption.
• Examples illustrate specific gene-drug-outcome relationships (e.g., UGT1A1 and irinotecan toxicity).
• Regulatory pathways and evidence standards for pharmacogenomic tests require further definition.

Conclusions:

• Personalized medicine, particularly pharmacogenomics, has transformative potential but requires overcoming substantial barriers.
• Clarification of regulatory requirements and development of robust evidence are crucial for widespread clinical translation.
• Continued research and education are essential to realize the full benefits of pharmacogenomic testing.